| Study Protocol Number | Study Title and Description |
|---|---|
| 25-2333 |
A Phase 3, Multicenter, Prospective, Randomized, Open-label Efficacy and Safety Study of Intravenous Brincidofovir versus Intravenous Cidofovir for Treatment of Adenovirus Infection in Pediatric and Adult Subjects After Allogeneic Hematopoietic Cell Transplantation (allo-HCT)
Primary Objective To assess efficacy of intravenous (IV) brincidofovir (BCV), compared with IV cidofovir (CDV), in subjects after allo-HCT with adenovirus (AdV) viremia. Secondary Objectives To assess the safety of IV BCV, compared with IV CDV, in subjects after allo-HCT with AdV viremia. To assess IV BCV pharmacokinetics (PK). |
| 22-1788 |
DEFIANCE: ClotTriever vs. Anticoagulation for DVT
The primary study objective is to compare the clinical outcomes of patients treated with an interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm) versus conservative medical management using anticoagulation therapy alone (Conservative Medical Management Arm) in the treatment of symptomatic unilateral iliofemoral DVT |
| 22-0998 |
CAR T-Cell Treatment for Children with Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia
In this study we want to learn more about a new treatment called CD19x22 CAR T cells. We want to see how well it works as a treatment for B-cell Acute Lymphoblastic Leukemia (B-ALL) when the cancer has come back after treatment or hasn’t responded to previous treatments. |
| 23-0001 |
Blood Disorder Symptomatology Outcomes Network Patient Reported Outcomes (BISON-PRO) Quality of Life Study
The primary objective of the BISON-PRO Database is to establish a prospective repository of real-world, longitudinally-collected patient-reported outcomes (PRO) and quality-of-life data for patients with both malignant and non-neoplastic blood disorders to support patient-centered research. |